140 related articles for article (PubMed ID: 32154745)
21. Prescription drug benefits: Rx for cost management--commentary.
Carlsen MA
Benefits Q; 1993; 9(3):81-8. PubMed ID: 10127207
[No Abstract] [Full Text] [Related]
22. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
23. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
Marshall LZ; Espinosa R; Starner CI; Gleason PP
J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
[No Abstract] [Full Text] [Related]
24. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
25. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
[TBL] [Abstract][Full Text] [Related]
26. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.
Goldman DP; Joyce GF; Karaca-Mandic P
Am J Manag Care; 2006 Jan; 12(1):21-8. PubMed ID: 16402885
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
Pauly NJ; Brown JD
J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
[TBL] [Abstract][Full Text] [Related]
28. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
29. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
30. Health Plan Enrollment and Disenrollment of Individuals With and Without Established Chronic Disease in a U.S. Commercially Insured and Medicare Advantage Population.
Chung H; Deshpande G; Zolotarjova J; Quimbo RA; Kern DM; Cochetti PT; Willey VJ
J Manag Care Spec Pharm; 2019 May; 25(5):612-620. PubMed ID: 31039058
[TBL] [Abstract][Full Text] [Related]
31. Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort Study.
Starner CI; Qiu Y; Karaca-Mandic P; Gleason PP
J Manag Care Spec Pharm; 2016 Dec; 22(12):1403-1410. PubMed ID: 27882841
[TBL] [Abstract][Full Text] [Related]
32. Association between health system specialty pharmacy use and health care costs among national sample of Medicare Advantage beneficiaries.
Hellems SS; Soni A; Fasching D; Smith BS; McManus DD
J Manag Care Spec Pharm; 2022 Feb; 28(2):244-254. PubMed ID: 35098745
[No Abstract] [Full Text] [Related]
33. Utilization and Cost of an Employer-Sponsored Comprehensive Primary Care Delivery Model.
Basu S; Zhang T; Gilmore A; Datta E; Kim EY
JAMA Netw Open; 2020 Apr; 3(4):e203803. PubMed ID: 32352529
[TBL] [Abstract][Full Text] [Related]
34. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
[TBL] [Abstract][Full Text] [Related]
35. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
36. Specialty drug and health care utilization vary by wage level in employer-sponsored health plans.
Sherman BW; Sils B; Kamin L; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):918-928. PubMed ID: 35722830
[No Abstract] [Full Text] [Related]
37. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
38. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
Johnsrud M; Lawson KA; Shepherd MD
J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
[TBL] [Abstract][Full Text] [Related]
39. What Happens When Employers Switch from a "Carve-Out" to a "Carve-In" Model of Managed Behavioral Health?
Ettner SL; Xu H; Azocar F
J Ment Health Policy Econ; 2019 Sep; 22(3):85-94. PubMed ID: 31811752
[TBL] [Abstract][Full Text] [Related]
40. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
